---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-016731"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:49:00.699363+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics reports Q3 net income $17.6M; Pfizer exercises TRACER capsid option

## Summary
- Collaboration revenue $41.1M (vs $1.5M YoY) driven by $40M Pfizer option exercise recognition.
- Net income $17.6M vs loss of $25.1M; cash $131.6M plus $10M Pfizer payment received in October.
- Pfizer exercised option to license novel capsid; $10M payment, up to $290M in milestones plus tiered royalties.
- Pipeline: lead development candidates for GBA1, SOD1, anti-tau programs expected Q4 2022 to H1 2023.
- Novartis option decision on TRACER capsids for up to 5 targets expected by March 2023.

## SEC filing metadata
- accession: 0001558370-22-016731
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000155837022016731/0001558370-22-016731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000155837022016731/vygr-20221108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-016731
- JSON: https://secwatch.observer/filing/0001558370-22-016731.json
- Plain text: https://secwatch.observer/filing/0001558370-22-016731.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.